Experimental gene injection aims to halt rare eye disease
NCT ID NCT07161544
Summary
This early-stage trial is testing a single gene therapy injection for people with Stargardt disease, a genetic condition that causes vision loss. The main goal is to see if the treatment is safe and well-tolerated. Researchers will also look for early signs that it might slow or stop the progression of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moorfields Eye Hospital NHS Foundation Trust
RECRUITINGLondon, England, EC1V 2PD, United Kingdom
-
Retina Consultants of Texas
RECRUITINGBellaire, Texas, 77401, United States
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact Email: •••••@•••••
-
Retina Vitreous Associates Medical Group
RECRUITINGLos Angeles, California, 90211, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
The Retina Clinic
RECRUITINGLondon, England, W1G 9AX, United Kingdom
Conditions
Explore the condition pages connected to this study.